Table 5.
Descriptive statistics of study population with a measurement of IgM.
| Pancreatic cancer N = 117 n (%) | No pancreatic cancer N = 29,802 n (%) | |
|---|---|---|
| Mean Age (years) (SD) | 60.9 (11.76) | 50.8 (16.25) |
| <55 | 36 (30.77) | 18,613 (62.46) |
| ≥55 | 81 (69.23) | 11,189 (37.54) |
| Gender | ||
| Men | 48 (41.03) | 10,852 (36.41) |
| Women | 69 (58.97) | 18,950 (63.59) |
| SES | ||
| Unclassified/missing | 18 (15.38) | 5,675 (19.04) |
| Low | 51 (43.59) | 12,759 (42.81) |
| High | 48 (41.03) | 11,368 (38.15) |
| Education | ||
| Missing | 8 (6.84) | 1,658 (5.56) |
| Low | 37 (31.62) | 7,885 (26.46) |
| Middle | 43 (36.75) | 12,585 (42.23) |
| High | 29 (24.79) | 7,674 (25,75) |
| Charlson comorbidity index | ||
| 0 | 88 (75.21) | 26,205 (87.93) |
| 1 | 20 (17.09) | 2,349 (7.88) |
| 2 | 6 (5.13) | 697 (2.34) |
| 3+ | 3 (2.56) | 551 (1.85) |
| Mean follow-up time (years) (SD) | 8.15 (5.53) | 15.4 (4.73) |
| Glucose (mmol/L) | ||
| Mean (SD) | 5.53 (1.59) | 5.19 (1.51) |
| <5.60 mmol/L | 60 (51.28) | 16,259 (54.56) |
| 5.60–6.99 mmol/L | 19 (16.24) | 3,140 (10.54) |
| ≥7.00 mmol/L | 8 (6.84) | 1,046 (3.51) |
| Missing | 30 (25.64) | 9,357 (31.40) |
| IgM (g/L) | ||
| Mean (SD) | 1.11 (0.72) | 1.28 (0.96) |
| <1.40 g/L | 90 (76.92) | 20,330 (68.22) |
| ≥1.40 g/L | 27 (23.08) | 9,472 (31.78) |